The SEC filings page for Strata Critical Medical, Inc. (Nasdaq: SRTA) provides access to the company’s regulatory disclosures as it executes its strategy in time-critical logistics and medical services for the U.S. healthcare industry. While no specific filings are listed here, Strata’s public communications reference documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which contain detailed financial statements, risk factors and management’s discussion of its organ logistics and medical services platform.
Through SEC filings, readers can review how Strata reports the performance of its air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion services, as well as perfusion staffing and equipment solutions offered under the Trinity Medical Solutions and Keystone Perfusion brands. The company also describes non-GAAP metrics like Adjusted EBITDA, Flight Profit, Flight Margin and various free cash flow measures, with reconciliations to GAAP figures typically presented in these filings or related materials.
Regulatory documents also summarize key corporate events that Strata highlights in its news releases, such as the divestiture of its Passenger business, the rebranding from Blade Air Mobility to Strata Critical Medical, the acquisition of Keystone Perfusion and the move to a single operating and reporting segment. Risk factor sections expand on themes the company mentions in press releases, including competition, reliance on transplant centers and organ procurement organizations, operational risks in organ transport and regulatory changes affecting its activities.
On Stock Titan, SEC filings for SRTA are supplemented with AI-powered summaries that explain complex sections in plain language, highlight important changes across reporting periods and help readers quickly identify disclosures related to organ logistics, medical services, acquisitions and non-GAAP performance measures. Real-time updates from EDGAR, combined with these summaries, make it easier to track how Strata’s regulatory reporting reflects its evolving business model in the U.S. healthcare and transplant ecosystem.
Strata Critical Medical, Inc. (SRTA) is the issuer named in a Schedule 13D reporting that Third Point LLC and Daniel S. Loeb, the management company’s chief executive officer, beneficially own 5,126,511 common shares, or approximately 5.8% of the class. The percentage calculation uses 88,466,806 shares outstanding as of July 28, 2026.
The Funds directly hold the shares, while Third Point LLC and Daniel S. Loeb report shared voting and dispositive power. The Funds state they expended $24,452,374 of their own investment capital to acquire the shares. The reporting persons say they may communicate with the company, its management or board, shareholders, and other parties about operational, governance, and strategic matters; they believe the company should explore strategic alternatives, including consideration of a potential sale.
Strata Critical Medical, Inc. (SRTA) lists a proposed sale of 100,000 Class A shares for the account of The Eric L. Affeldt Living Trust DTD 2/14/2005, with an aggregate market value of $517,000. UBS Financial Services Inc. is named in the notice, and the listed sale date is October 2, 2026. Eric L. Affeldt is identified as a trustee of the trust and a former board member of Strata Critical Medical. The notice also lists a 200,000-share acquisition connected with the August 29, 2025 merger with Blade Air Mobility, Inc., and reports 10,000 shares sold on August 26, 2026, with a reported value of $61,262.
Strata Critical Medical, Inc. Co-CEO and General Counsel Melissa M. Tomkiel acquired 177,858 Class A common shares on September 24, 2026, after the Compensation Committee certified that performance criteria for her performance-based restricted stock units were satisfied; the units were granted on August 29, 2026. On September 24, the issuer withheld 90,797 shares at $5.27 per share to satisfy tax withholding obligations related to PSU vesting.
Strata Critical Medical, Inc. (SRTA) Co-CEO and CFO William A. Heyburn acquired 177,858 shares of Class A common stock on September 24, 2026, after the Compensation Committee certified that performance criteria for performance-based restricted stock units granted August 29, 2025, had been satisfied. On that date, the issuer withheld 98,356 shares at a reported $5.27 per share to satisfy tax withholding obligations related to PSU vesting.
Strata Critical Medical, Inc. (SRTA) reported that officer Louis R. Verdetto, CEO, Clinical Services, had 5,697 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations related to vesting restricted stock units at $5.31 per share. After this withholding, he holds 1,128,096 shares directly and 132,232 shares indirectly through the LOUIS VERDETTO IRREVOCABLE TRUST DATED AUGUST 20 2025. No Rule 10b5-1 trading plan is reported.
Strata Critical Medical, Inc. (SRTA) reported that officer Scott M. Wunsch, CEO, Logistics, had 5,711 shares of Class A common stock withheld on September 8, 2026 to pay tax liabilities tied to vesting restricted stock units, at a reference value of $5.31 per share; no Rule 10b5-1 plan is reported. After this tax-withholding disposition, he holds 663,043 shares directly and 382,987 shares indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. (SRTA) reported that Chief Accounting Officer Amir Cohen had 4,645 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations related to vesting restricted stock units. The shares were valued at $5.31 per share for this purpose, and Cohen now holds 177,154 shares directly.
Strata Critical Medical, Inc. (SRTA) reported that Co-CEO and General Counsel Melissa M. Tomkiel had 29,730 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. This tax-withholding disposition left her holding 2,066,617 shares directly. No Rule 10b5-1 trading plan is reported for this transaction.
Strata Critical Medical, Inc. (SRTA) reported that Co-CEO and CFO William A. Heyburn had 31,671 shares of Class A common stock withheld on September 8, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This was a share withholding, not an open-market sale, and Heyburn now directly holds 1,678,348 shares of Class A common stock.
Strata Critical Medical, Inc. (SRTA) received an Amendment No. 3 to a Schedule 13G from Steele ExpCo Holdings, LLC, KSL Capital Partners V GP, LLC and Eric Charles Resnick reporting their ownership of Class A Common Stock. The reporting group beneficially owns 7,923,000 shares of Class A Common Stock, representing 9.0% of the class, based on 88,466,806 shares outstanding as of July 28, 2026. These shares are held directly by Steele ExpCo Holdings, LLC, with KSL Capital Partners V GP, LLC as its managing member and Eric Charles Resnick as managing member of that entity, so they may be deemed to share voting and dispositive power over these shares. The amendment notes that on May 7, 2026, 4,500,000 warrants to purchase Class A Common Stock held by Steele ExpCo Holdings, LLC expired in accordance with their terms.